Role of PRL Phosphatases in Ovarian Cancer
Author Information
Author(s): Reuven Reich, Hadar Shany, Davidson Ben
Primary Institution: The Hebrew University of Jerusalem
Hypothesis
The study investigates the expression and clinical significance of PRL phosphatases in ovarian carcinoma.
Conclusion
PRL-1 and PRL-2 expression is associated with longer survival in ovarian carcinoma, while PRL-3 has no clinical role.
Supporting Evidence
- PRL-1 mRNA levels were significantly higher in effusions compared to solid tumors (p < 0.001).
- Higher levels of PRL-1 and PRL-2 mRNA correlated with longer overall survival (p = 0.022 and p = 0.02, respectively).
- PRL-3 protein expression was significantly higher in primary diagnosis pre-chemotherapy compared to post-chemotherapy disease recurrence (p = 0.003).
Takeaway
This study found that two proteins, PRL-1 and PRL-2, can help patients with ovarian cancer live longer, but another protein, PRL-3, doesn't seem to help.
Methodology
The study analyzed mRNA expression using RT-PCR and protein expression using Western blotting in various tumor samples.
Limitations
The study's findings may be limited by the lack of patient-matched samples and the retrospective nature of the analysis.
Participant Demographics
The study included 90 patients with ovarian carcinoma effusions, predominantly of the serous type.
Statistical Information
P-Value
p = 0.001 for PRL-1 and PRL-2 expression in effusions
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website